Medicis Investor Sues To Halt $2.6B Valeant Buyout
A Medicis Pharmaceutical Corp. shareholder launched a class action on Tuesday challenging Valeant Pharmaceuticals International Inc.'s $2.6 billion bid for the dermatological drugmaker, saying the deal shortchanges investors....To view the full article, register now.
Already a subscriber? Click here to view full article